



Simavita releases ASX Appendix 4C for the quarter ended September 30, 2015 and provides market uptake data for SIM™

For Immediate Release:

October 30, 2015

Sydney, Australia – Simavita Limited (ASX: SVA; TSX-V: SV) (“Simavita” or the “Company”), a global leader in the digital healthcare sector, is pleased to release its ASX Appendix 4C for the quarter ended September 30, 2015. The Company is also pleased to provide data demonstrating the growing adoption of SIM™ in both domestic and international markets.

ASX Appendix 4C – September 30, 2015

Cash receipts from customers for the quarter were \$223,816. This figure represents an increase of 148% over the total cash receipts from customers for the corresponding quarter in 2014 of \$90,223.

Highlights during and immediately post the September quarter included:

- Execution of sales and marketing agreement with Paul Hartmann Pty. Ltd. to further expand the distribution of SIM™ in the Australian marketplace.
- Global roll out of the Software as a Service (SaaS) business model commenced.
- Two Canadian distribution partners signed up to distribute SIM™ on a non-exclusive basis in Canada and, post the quarter, the first Canadian chain signed up under a SaaS model.
- The Company has further strengthened its global patent portfolio with the granting of six new patents during the quarter.
- Distribution arrangements with Medline modified, transitioning to a non-exclusive distribution agreement in parallel with the strengthening of Simavita’s own US sales and marketing team.

Immediately post the quarter:

- Significant funding (\$469,450) awarded by the Queensland Health Department to fund the deployment of SIM™ in rehabilitation wards of two major hospitals in Brisbane over the next two years.
- Sales of SIM™ in the North American market continue to grow, with new agreements signed representing 2,500 beds, and further pilots underway as part of the expanding North American pipeline.

Simavita’s CEO, Mrs. Philippa Lewis commented, “We have worked hard in the September quarter to reset our approach to business development in the North American market, and are now better positioned for flexible growth. The amendment to our distribution agreement with Medline has been key to enabling Simavita to work directly in the region, and we're starting to see early results from the change.

“In addition, the recently-awarded funding by the Queensland Department of Health for the deployment of SIM™ in the acute care rehab market opens up a potentially large and exciting market for our products. This, coupled with sales and marketing agreements in Australia with Hartmann and Buzl, supports and reinforces our direct sales strategy”, she said.

Market uptake data for SIM™

As a result of the highlights noted above, and other important initiatives such as the release of the Version 4.10 sensor, the global deployment of SIM™ has continued to increase during the September quarter.

Subsequent to the end of the September quarter, a significant proportion of the contracted sites awaiting deployment of SIM™ have commenced using the technology.

As announced on October 14, 2015, the Company has the equivalent of 18 contracted SaaS sites in the rehabilitation wards of the two large public hospitals in Queensland following the successful applications made under the Queensland Department of Health's New Technology Funding and Evaluation Program.

This brings the combined total number of deployed and contracted sites to well over 100.

In addition to the above, the Company's Danish distributor, Abena, has recently ordered further inventory of SIM™ assessments which are now being deployed across a number of Danish sites.

The Company is also pleased to note the increasing number of pilots scheduled in the coming months. Many pilots are being conducted in facilities that are part of larger groups and commonly pilots lead to the deployment of SIM™ across the group.

The Company's SaaS business model includes the SIM™ software and consumables which are invoiced and paid on a monthly basis, and recognised as revenue each month, as is common with other similar SaaS models. Importantly, as the Company's customer base increases, these payments will form a valuable annuity stream for Simavita

"We are confident that the Company's growing pipeline, supported by the encouraging number of contracted sites together with the pilots that are now scheduled, will result in growing sales of SIM™ over the coming quarters", Mrs. Lewis added.

For further information, see our website (www.simavita.com) or contact the persons outlined below.

Company	Media and Investor Relations
Philippa Lewis, Chief Executive Officer T: +61 2 8405 6381	Jane Lowe E: jane.lowe@irdepartment.com.au T: +61 411 117 774
Thomas Howitt, Chief Financial Officer T: +61 418 351 127	

About Simavita

Simavita is a digital healthcare company that has developed an innovative software platform. The first application for the platform is a world first solution for the management of urinary incontinence, with a focus on the elderly. This platform technology is an instrumented incontinence assessment application that provides evidence-based incontinence management care plans to the residential aged care market.

About SIM™

SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit www.simavita.com.

The TSX Venture Exchange ("TSX-V") has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither the TSX-V nor its Regulation Services Provider (as that term is defined in policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this Release.

Except for historical information, this announcement may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, the anticipated date of on the ASX, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Forward-Looking Information

This document may contain “forward-looking information” within the meaning of Canadian securities laws (“forward-looking information”). This forward-looking information is given as of the date of this document.

Forward-looking information relates to future events or future performance and reflects Simavita management’s expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct.

In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or information that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita’s interim and annual financial statements and management’s discussion and analysis of those statements. Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity

SIMAVITA LIMITED

ARBN

165 831 309

Quarter ended ("current quarter")

30 SEPTEMBER 2015

Consolidated statement of cash flows

	Current Quarter (September 2015) A\$	Year to date (three months) A\$
Cash flows related to operating activities		
1.1 Receipts from customers	223,816	223,816
1.2 Payments for		
(a) staff costs	(1,912,697)	(1,912,697)
(b) advertising and marketing	(476,122)	(476,122)
(c) research and development	(130,192)	(130,192)
(d) operating lease payments	(94,904)	(94,904)
(e) other working capital	(574,894)	(574,894)
(f) transaction expenses	-	-
1.3 Dividends received	-	-
1.4 Interest and items of a similar nature received	42,685	42,685
1.5 Interest and other costs of finance paid	-	-
1.6 R&D tax credit	-	-
1.7 Grant and other income	-	-
Net operating cash flows	(2,922,308)	(2,922,308)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Consolidated statement of cash flows (cont.)

	Current Quarter (September 2015) A\$	Year to date (three months) A\$
1.8 Net operating cash flows (carried forward)	(2,922,308)	(2,922,308)
Cash flows related to investing activities		
1.9 Payment for the acquisition of:		
a) businesses (item 5)	-	-
b) equity investments	-	-
c) intellectual property	-	-
d) physical non-current assets	(25,022)	(25,022)
e) other non-current assets	(13,463)	(13,463)
1.10 Proceeds from the disposal of:		
a) businesses (item 5)	-	-
b) equity investments	-	-
c) intellectual property	-	-
d) physical non-current assets	-	-
e) joint venture interest	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other	-	-
Net investing cash flows	(38,485)	(38,485)
1.14 Total operating and investing cash flows	(2,960,793)	(2,960,793)
Cash flows related to financing activities		
1.15 Proceeds from the issue of shares	-	-
1.16 Equity transaction costs	-	-
1.17 Net repayment of borrowings	-	-
1.18 Advances to third parties	-	-
1.19 Dividends paid	-	-
1.20 Other	-	-
Net financing cash flows	-	-
Net increase / (decrease) in cash held	(2,960,793)	(2,960,793)
1.21 Cash at beginning of quarter / year to date	9,027,722	9,027,722
1.22 Exchange rate adjustments	34,469	34,469
1.23 Cash at end of quarter	6,101,398	6,101,398

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related entities

		Current Quarter \$A
1.24	Aggregate amount of payments to the parties included in item 1.2	80,266
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

The amount included at Item 1.24 includes amounts paid to Directors during the quarter in respect of fees and superannuation totalling \$80,266. The amount included at Item 1.24 does not include amounts paid to the Chief Executive Officer in her capacity as an Executive of the Company.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

None during the quarter under review

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

None during the quarter under review

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available A\$	Amount used A\$
3.1	Loan facilities	-	-
3.2	Credit standby arrangements Hire purchase facility	-	-

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows:

	Current Quarter (September 2015) A\$	Previous Quarter (June 2015) A\$
4.1 Cash on hand and at bank	1,101,398	4,027,722
4.2 Term deposits	5,000,000	5,000,000
4.3 Bank overdraft	-	-
4.4 Commercial Bills of Exchange	-	-
Total cash at end of quarter (item 1.23)	6,101,398	9,027,722

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	Not applicable	Not applicable
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here: Date: **30 October 2015**
Chief Executive Officer

Print name: **Philippa M. Lewis**

+ See chapter 19 for defined terms.

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.